Lincoln [LINCOLN] vs Windlas Biotech [WINDLAS] Detailed Stock Comparison

Lincoln Pharmaceuticals Ltd.

NSE
Loading...

Windlas Biotech Ltd.

NSE
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Lincoln Pharmaceuticals Ltd. wins in 16 metrics, Windlas Biotech Ltd. wins in 4 metrics, with 0 ties. Lincoln Pharmaceuticals Ltd. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Lincoln Pharmaceuticals Ltd. Windlas Biotech Ltd. Better
P/E Ratio (TTM) 13.91 27.93 Lincoln Pharmaceuticals Ltd.
Price-to-Book Ratio 1.71 3.45 Lincoln Pharmaceuticals Ltd.
Debt-to-Equity Ratio 0.01 5.84 Lincoln Pharmaceuticals Ltd.
PEG Ratio 0.37 -6.31 Lincoln Pharmaceuticals Ltd.
EV/EBITDA 9.75 14.83 Lincoln Pharmaceuticals Ltd.
Profit Margin (TTM) 13.47% 7.69% Lincoln Pharmaceuticals Ltd.
Operating Margin (TTM) 11.95% 7.16% Lincoln Pharmaceuticals Ltd.
EBITDA Margin (TTM) 11.95% 7.16% Lincoln Pharmaceuticals Ltd.
Return on Equity 12.26% 12.06% Lincoln Pharmaceuticals Ltd.
Return on Assets (TTM) 10.33% 8.02% Lincoln Pharmaceuticals Ltd.
Free Cash Flow (TTM) $737.71M $159.93M Lincoln Pharmaceuticals Ltd.
Dividend Yield 0.32% 1.23% Windlas Biotech Ltd.
1-Year Return 8.56% -11.61% Lincoln Pharmaceuticals Ltd.
Price-to-Sales Ratio (TTM) 1.87 2.14 Lincoln Pharmaceuticals Ltd.
Enterprise Value $9.86B $16.09B Windlas Biotech Ltd.
EV/Revenue Ratio 1.51 1.85 Lincoln Pharmaceuticals Ltd.
Gross Profit Margin (TTM) 54.33% 38.44% Lincoln Pharmaceuticals Ltd.
Revenue per Share (TTM) $325 $414 Windlas Biotech Ltd.
Earnings per Share (Diluted) $43.85 $31.45 Lincoln Pharmaceuticals Ltd.
Beta (Stock Volatility) 0.36 0.22 Windlas Biotech Ltd.

Lincoln Pharmaceuticals Ltd. vs Windlas Biotech Ltd. Stock Performance Analysis

Loading Price Chart...

LINCOLN
WINDLAS

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Lincoln Pharmaceuticals Ltd.2.65%5.35%1.36%11.75%34.87%36.09%
Windlas Biotech Ltd.-0.62%0.61%5.11%16.08%4.89%2.18%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Lincoln Pharmaceuticals Ltd.8.56%64.45%104.57%356.31%195.59%195.59%
Windlas Biotech Ltd.-11.61%173.72%124.79%124.79%124.79%124.79%

Performance & Financial Health Analysis: Lincoln Pharmaceuticals Ltd. vs Windlas Biotech Ltd.

MetricLINCOLNWINDLAS
Market Information
Market Cap i₹12.25B₹18.15B
Market Cap CategorySmall capSmall cap
10 Day Avg. Volume i51,59059,253
90 Day Avg. Volume i43,78045,178
Last Close₹652.95₹819.20
52 Week Range₹440.00 - ₹770.00₹697.40 - ₹1,097.90
% from 52W High-15.20%-25.38%
All-Time High₹979.50 (Dec 09, 2024)₹1,198.25 (Nov 04, 2024)
% from All-Time High-33.34%-31.63%
Growth Metrics
Quarterly Revenue Growth0.14%0.20%
Quarterly Earnings Growth0.38%-0.04%
Financial Health
Profit Margin (TTM) i0.13%0.08%
Operating Margin (TTM) i0.12%0.07%
Return on Equity (TTM) i0.12%0.12%
Debt to Equity (MRQ) i0.015.84
Cash & Liquidity
Book Value per Share (MRQ)₹357.45₹254.44
Cash per Share (MRQ)₹115.79₹125.24
Operating Cash Flow (TTM) i₹967.87M₹396.84M
Levered Free Cash Flow (TTM) i₹823.46M₹609.94M
Dividends
Last 12-Month Dividend Yield i0.32%1.23%
Last 12-Month Dividend i₹1.80₹11.30

Valuation & Enterprise Metrics Analysis: Lincoln Pharmaceuticals Ltd. vs Windlas Biotech Ltd.

MetricLINCOLN (Apr 24, 2026)WINDLAS (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i13.9127.93
Forward P/E iN/AN/A
PEG Ratio i0.37-6.31
Price to Sales (TTM) i1.872.14
Price to Book (MRQ) i1.713.45
Market Capitalization
Market Capitalization i₹12.25B₹18.15B
Enterprise Value i₹9.86B₹16.09B
Enterprise Value Metrics
Enterprise to Revenue i1.511.85
Enterprise to EBITDA i9.7514.83
Risk & Other Metrics
Beta i0.360.22
Book Value per Share (MRQ) i₹357.45₹254.44

Financial Statements Comparison: Lincoln Pharmaceuticals Ltd. vs Windlas Biotech Ltd.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricLINCOLN (2025)WINDLAS (2025)
Revenue/Sales i6.15B7.55B
Cost of Goods Sold i2.93B4.72B
COGS % of Revenue i47.6%62.5%
Gross Profit i3.23B2.83B
Gross Margin i52.4%37.5%
Research & Development iN/A62.51M
Operating Income (EBIT) i892.06M666.10M
Operating Margin i14.5%8.8%
EBITDA i1.17B971.54M
EBITDA Margin i19.0%12.9%
Pre-Tax Income i1.09B797.58M
Pre-Tax Income % of Revenue i17.7%10.6%
Income Tax i268.42M187.64M
Income Tax % of Revenue i4.4%2.5%
Net Income (Profit) i823.46M609.94M
Profit Margin i13.4%8.1%

Balance Sheet & Liquidity Metrics

MetricLINCOLN (2025)WINDLAS (2025)
Cash & Equivalents i134.14M4.24M
Total Current Assets i5.00B5.25B
Total Current Assets % of Revenue i81.3%69.5%
Total Current Liabilities i1.06B2.49B
Total Current Liabilities % of Revenue i17.3%33.0%
Long-Term Debt iN/A22.51M
Long-Term Debt % of Revenue i0.0%0.3%
Total Shareholders Equity i6.72B5.06B
Retained Earnings i5.86B2.75B
Retained Earnings % of Revenue i95.2%36.4%
Property, Plant & Equipment i220.84M65.84M

Cash Flow Statement Comparison

MetricLINCOLN (2025)WINDLAS (2025)
Operating Cash Flow i967.87M396.84M
Operating Cash Flow % of Revenue i15.7%5.3%
Capital Expenditures i-189.07M-519.97M
Free Cash Flow i737.71M159.93M
FCF Margin i12.0%2.1%
Debt Repayment i-694.17M0
Common Stock Repurchase iN/A0

Short Interest & Institutional Ownership Analysis

MetricLINCOLNWINDLAS
Shares Short iN/AN/A
Short Ratio iN/AN/A
Short % of Float iN/AN/A
Shares Outstanding i20.03M21.11M
Float Shares i9.26M7.62M
% Held by Insiders i55.10%65.75%
% Held by Institutions i1.03%8.46%
% Held by Public i43.87%25.79%

Dividend Analysis & Yield Comparison: Lincoln Pharmaceuticals Ltd. vs Windlas Biotech Ltd.

MetricLINCOLNWINDLAS
Last 12-Month Dividend i₹1.80₹11.30
Last 12-Month Dividend Yield i0.32%1.23%
3-Year Avg Annual Dividend i₹1.70₹6.27
3-Year Avg Dividend Yield i0.29%0.96%
3-Year Total Dividends i₹5.10₹18.80
Ex-Dividend DateSep 12, 2025Jul 21, 2025